Core Viewpoint - Angli Kang (002940.SZ) has announced its participation in the national organized procurement for the continuation of products whose agreements have expired, indicating potential selection for some of its products in the upcoming procurement process [1] Group 1 - The company is involved in the national organized procurement for the first to eighth batches of products whose agreements have expired [1] - The procurement office released the proposed selection results for the continuation of procurement on February 10, 2026 [1] - Some of the company's products are expected to be selected in this continuation procurement process [1]

证券代码：002940 证券简称：昂利康 公告编号：2026-003 浙江昂利康制药股份有限公司 关于公司产品拟中选国家药品接续采购的公告 二、本次拟中选对公司的影响 本次接续采购品种为第 1-8 批国家组织集采协议期满的品种，约定采购量以 医药机构填报各企业采购品种需求量为基数，按照中选价格梯度确定带量比例。 采购周期自中选结果实际执行日起至 2028 年 12 月 31 日。 公司上述拟中选的产品 2024 年度合计销售额为 21,420 万元，占公司 2024 年度营业收入比例为 13.93%。若公司后续签订采购合同并实施后，将有利于进 一步扩大产品的销售规模，提高市场占有率，提升公司品牌影响力，对公司的未 来经营业绩产生积极的影响。 三、风险提示 1、上述产品拟中选的公示期为 2026 年 2 月 10 日至 2026 年 2 月 12 日，中 标结果尚具有一定的不确定性。 2、上述产品相关采购合同尚未签订，中标数量也未明确，后续事项及对公 司的影响程度尚具有不确定性。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 近日，浙江昂利康制药股份有限公司（ ...

Group 1: Financial Performance - The company expects a net profit attributable to shareholders for the year 2025 to be between 110 million and 138 million yuan, representing a year-on-year growth of 36.93% to 71.78%. The main reasons for this performance change include a reduction in new project initiations for generic drug R&D, leading to decreased R&D expenses, while growth in formulation business sales offset some decline in raw material drug business [2] Group 2: Product Development - The company continues to invest in innovative drugs, with its core product, ALK-N001 for injection, having received clinical trial approval in April 2025 and currently in Phase I clinical trials. Additionally, the company plans to advance clinical trials for products like ALK-N002 in relevant indications [3] Group 3: Capital Increase - In November 2025, the company disclosed a plan to issue A-shares to specific investors, aiming to raise no more than 1.16 billion yuan, primarily for "innovative drug R&D and industrialization projects." This plan requires approval from the company's shareholders' meeting, Shenzhen Stock Exchange, and registration consent from the China Securities Regulatory Commission before implementation [4] Group 4: Company Recognition - Recently, the company was recognized for its R&D investments by being included in the "Top 200 Private Enterprises in Zhejiang Province for R&D Investment in 2025" and the "Top 200 for Invention Patents," reflecting its acknowledged innovation capabilities [5]

Group 1 - The company, Anglikang, forecasts a net profit attributable to shareholders for 2025 between 110 million to 138 million yuan, representing a year-on-year growth of 36.93% to 71.78% [1] - The net profit after deducting non-recurring gains and losses is expected to be between 71 million to 99 million yuan, with a year-on-year increase of 46.68% to 104.52%, indicating a significant improvement in core profitability [1] - The growth in performance is attributed to the company's proactive reduction in new project approvals for generic drugs and a decrease in R&D expenses, alongside the deferral of a 100 million yuan upfront payment due to internal approval delays for the ALK-N002 project [1] Group 2 - Anglikang has established a comprehensive industrial chain from pharmaceutical intermediates and raw materials to finished formulations, focusing on key therapeutic areas such as cardiovascular, oral cephalosporins, and nephrology [2] - The company has developed several market-leading products, including the first domestic cephalosporin sustained-release tablet to pass the consistency evaluation, maintaining a leading market share [2] - In response to national policies promoting innovative drug development, Anglikang is actively exploring the development of modified new drugs and innovative drugs, accelerating its strategic push in this area [2] Group 3 - The company plans to raise 1.16 billion yuan through a private placement of A-shares to fund "innovative drug research and industrialization projects," focusing on clinical development and commercialization of innovative drugs for cancer treatment [3] - The injection drug ALK-N001 has received clinical trial approval and is currently in Phase I trials, with plans to advance clinical trials for ALK-N001 and ALK-N002 in relevant indications [3] - Anglikang has been recognized in 2025 as one of the top 200 companies in R&D investment and patent inventions in Zhejiang Province, reflecting its comprehensive strength in innovation [3]

Core Viewpoint - The company expects a significant increase in net profit for the year 2025, with projections ranging from 110 million to 138 million yuan, representing a year-on-year growth of 36.93% to 71.78% [2]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [1]. - The profit forecast is based on preliminary calculations by the company's finance department and has not yet been audited by an external accounting firm [1][2]. Group 2: Reasons for Performance Change - The expected increase in net profit is attributed to a reduction in R&D expenses compared to the previous year, primarily due to fewer new projects in generic drug development and delays in the internal approval process for a strategic cooperation agreement with a partner company [2]. - Despite a significant decline in sales volume for certain products due to low demand and price drops, the company's formulation business has seen rapid growth driven by new product launches and successful bidding in centralized procurement [2].

Core Viewpoint - The company, Anglikon, announced an expected net profit attributable to shareholders for the fiscal year 2025, ranging from 110 million to 138 million yuan, indicating a year-on-year growth of 36.93% to 71.78% [2] Financial Performance - The projected net profit for 2025 is estimated between 110 million yuan and 138 million yuan [2] - This represents a significant increase compared to the previous year's performance, with growth rates between 36.93% and 71.78% [2]

2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：自愿性业绩预告 （1）以区间数进行业绩预告的 单位：万元 | 项 目 | | 本报告期 | | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股东的净利润 | | 11,000 | ～ | 13,800 | 8,033.45 | | | 比上年同期增长 | 36.93% | ～ | 71.78% | | | 扣除非经常性损益后的净利润 | | 7,100 | ～ | 9,900 | 4,840.59 | | | 比上年同期增长 | 46.68% | ～ | 104.52% | | 证券代码：002940 证券简称：昂利康 公告编号：2026-002 浙江昂利康制药股份有限公司 三、业绩变动原因说明 公司预计 2025 年度归属于上市公司股东的净利润为 11,000 万元～13,800 万元，同比增长 ...

1月14日，巴基斯坦国家关税委员会发布第ADC68号案件的最新公告，对原产于或进口自中国的头孢氨 苄（Cefadroxil）作出反倾销肯定性终裁，决定对涉案产品征收反倾销税，具体如下：生产商/出口商浙 江昂利康制药股份有限公司税率为8.61%、中国其他生产商/出口商为11.81%，措施自2025年9月17日起 生效，有效期为五年。本案涉及巴基斯坦税号2941.9090项下的产品，产品用于治疗细菌引起的感染， 如皮肤、咽喉、扁桃体、尿路等感染。作为仅供出口的原材料或用于外国援助项目以及符合《1969年海 关法》规定的任何出口或外国援助项目免税计划的涉案产品不适用反倾销税。 ...

证券代码：002940 证券简称：昂利康 公告编号：2026-001 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 登录新浪财经APP 搜索【信披】查看更多考评等级 浙江昂利康制药股份有限公司 关于子公司通过高新技术企业重新认定的公告 特此公告。 浙江昂利康制药股份有限公司 董 事 会 2026年1月16日 近日，浙江昂利康制药股份有限公司（以下简称"公司"）控股子公司浙江昂利泰制药有限公司（以下简 称"昂利泰"）收到由浙江省经济和信息化厅、浙江省财政厅、国家税务总局浙江省税务局联合颁发的 《高新技术企业证书》，证书编号：GR202533009362，发证日期：2025年12月19日，有效期三年。 本次系昂利泰高新技术企业证书有效期满所进行的重新认定，根据《中华人民共和国企业所得税》以及 国家对高新技术企业的相关税收规定，昂利泰自本次通过高新技术企业重新认定后连续三年（即2025 年、2026年、2027年）继续享受高新技术企业的相关优惠政策，按15%的税率缴纳企业所得税。 2025年度昂利泰已按15%的税率预缴企业所得税，以上税收优惠政策不影响2025年度 ...

（文章来源：证券日报） 证券日报网讯 1月15日，昂利康发布公告称，公司控股子公司浙江昂利泰制药有限公司收到由浙江省经 济和信息化厅、浙江省财政厅、国家税务总局浙江省税务局联合颁发的《高新技术企业证书》，本次系 昂利泰高新技术企业证书有效期满所进行的重新认定。 ...